Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Holding ARCT?
Track your performance easily
ARCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.52 - $45.00
Previous Close$21.1
Volume261.75K
Average Volume (3M)556.56K
Market Cap
$565.99M
Enterprise Value$332.63M
Total Cash (Recent Filing)$260.33M
Total Debt (Recent Filing)$26.96M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 06, 2024EPS Estimate
-$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding27,042,246
10 Day Avg. Volume301,976
30 Day Avg. Volume556,560
Standard Deviation0.32
R-Squared0.18
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.19
Price to Sales (P/S)3.85
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda-4.96
Forecast
1Y Price Target
$72.43Price Target Upside243.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Arcturus Therapeutics News
PremiumCompany Announcements
Arcturus Therapeutics Releases Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Commercial LaunchKostaive commercial launch and potential development of a COVID/Flu combo vaccine are expected to yield significant revenue to ARCT.
PartnershipPartnership with global vaccine leader CSL positions ARCT to take share in the evolving endemic COVID market.
Vaccine EfficacyNature Communications reported that a two-dose primary vaccination of Kostaive was 100% effective against severe COVID-19 in healthy 18-59 year-olds; more than 90% effective in older people and those with co-morbidities.
Bears Say
Future RevenueThere are new questions about the robustness of Vertex's future CF revenues if genetic therapies are advanced.
Revenue RecognitionThe timing of revenue recognition is still TBD given the partnership structure: Meiji reports sales to CSL who then determines ARCT's share.
Therapy EligibilitySome patients are ineligible for modulator therapy due to their genetic mutation or other health issues.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $17.52 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Currently, no data Available
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 67 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Aug 05, 2024. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$1.498 by $0.858.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -$1.22.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,042,246 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.64 in its last earnings report, beating expectations of -$1.498. Following the earnings report the stock price went up 0.202%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 48M.
---
Arcturus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.43 (243.27% Upside)
$72.43 (243.27% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 299.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.99%
12-Months-Change
Fundamentals
Return on Equity
-25.32%
Trailing 12-Months
Asset Growth
-9.76%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Company Deck
---
ARCT Earnings Call
Q2 2024
0:00 / 0:00
---
ARCT Stock 12 Month Forecast
Average Price Target
$72.43
▲(243.27% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-21.74%
assigned a buy rating 26 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -21.74% per trade.
---